[{"orgOrder":0,"company":"Guangdong Provincial People's Hospital","sponsor":"Shenzhen Chipscreen Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Chidamide","moa":"enzyme inhibitors: inhibitors of histone deacetylase","graph1":"Oncology","graph2":"Undisclosed","graph3":"Guangdong Provincial People's Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Guangdong Provincial People's Hospital \/ Shenzhen Chipscreen Biosciences","highestDevelopmentStatusID":"1","companyTruncated":"Guangdong Provincial People's Hospital \/ Shenzhen Chipscreen Biosciences"},{"orgOrder":0,"company":"Tang-Du Hospital","sponsor":"Shenzhen Chipscreen Biosciences | Zhejiang University | First Affiliated Hospital of Guangxi Medical University","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Cytotoxic Drug","year":"2016","type":"Inapplicable","leadProduct":"Chidamide","moa":"enzyme inhibitors: inhibitors of histone deacetylase","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Tang-Du Hospital","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tang-Du Hospital \/ Shenzhen Chipscreen Biosciences | Zhejiang University | First Affiliated Hospital of Guangxi Medical University","highestDevelopmentStatusID":"9","companyTruncated":"Tang-Du Hospital \/ Shenzhen Chipscreen Biosciences | Zhejiang University | First Affiliated Hospital of Guangxi Medical University"},{"orgOrder":0,"company":"Sun Yat-sen University","sponsor":"Shenzhen Chipscreen Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Chidamide","moa":"enzyme inhibitors: inhibitors of histone deacetylase","graph1":"Oncology","graph2":"Phase II","graph3":"Sun Yat-sen University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sun Yat-sen University \/ Shenzhen Chipscreen Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Sun Yat-sen University \/ Shenzhen Chipscreen Biosciences"},{"orgOrder":0,"company":"Tang-Du Hospital","sponsor":"Shenzhen Chipscreen Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Cytotoxic Drug","year":"2015","type":"Inapplicable","leadProduct":"Chidamide","moa":"enzyme inhibitors: inhibitors of histone deacetylase","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Tang-Du Hospital","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tang-Du Hospital \/ Shenzhen Chipscreen Biosciences","highestDevelopmentStatusID":"9","companyTruncated":"Tang-Du Hospital \/ Shenzhen Chipscreen Biosciences"},{"orgOrder":0,"company":"GNT Biotech & Medicals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Chidamide","moa":"enzyme inhibitors: inhibitors of histone deacetylase","graph1":"Oncology","graph2":"Phase II","graph3":"GNT Biotech & Medicals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GNT Biotech & Medicals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GNT Biotech & Medicals \/ Undisclosed"},{"orgOrder":0,"company":"GNT Biotech & Medicals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Chidamide","moa":"enzyme inhibitors: inhibitors of histone deacetylase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GNT Biotech & Medicals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GNT Biotech & Medicals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"GNT Biotech & Medicals \/ Undisclosed"},{"orgOrder":0,"company":"Shenzhen Chipscreen Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2016","type":"Inapplicable","leadProduct":"Chidamide","moa":"enzyme inhibitors: inhibitors of histone deacetylase","graph1":"Oncology","graph2":"Phase I","graph3":"Shenzhen Chipscreen Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shenzhen Chipscreen Biosciences \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Shenzhen Chipscreen Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"HUYA Bioscience International","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Chidamide","moa":"enzyme inhibitors: inhibitors of histone deacetylase","graph1":"Oncology","graph2":"Phase II","graph3":"HUYA Bioscience International","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"HUYA Bioscience International \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"HUYA Bioscience International \/ Undisclosed"},{"orgOrder":0,"company":"HUYA Bioscience International","sponsor":"Shenzhen Chipscreen Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Chidamide","moa":"enzyme inhibitors: inhibitors of histone deacetylase","graph1":"Oncology","graph2":"Phase II","graph3":"HUYA Bioscience International","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"HUYA Bioscience International \/ Shenzhen Chipscreen Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"HUYA Bioscience International \/ Shenzhen Chipscreen Biosciences"},{"orgOrder":0,"company":"Shenzhen Chipscreen Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2015","type":"Inapplicable","leadProduct":"Chidamide","moa":"enzyme inhibitors: inhibitors of histone deacetylase","graph1":"Oncology","graph2":"Phase III","graph3":"Shenzhen Chipscreen Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shenzhen Chipscreen Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Shenzhen Chipscreen Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Shenzhen Chipscreen Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2013","type":"Inapplicable","leadProduct":"Chidamide","moa":"enzyme inhibitors: inhibitors of histone deacetylase","graph1":"Oncology","graph2":"Phase II","graph3":"Shenzhen Chipscreen Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shenzhen Chipscreen Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shenzhen Chipscreen Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Shenzhen Chipscreen Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Chidamide","moa":"enzyme inhibitors: inhibitors of histone deacetylase","graph1":"Oncology","graph2":"Phase II","graph3":"Shenzhen Chipscreen Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shenzhen Chipscreen Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shenzhen Chipscreen Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"HUYA Bioscience International","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2020","type":"Inapplicable","leadProduct":"Chidamide","moa":"||enzyme inhibitors: inhibitors of histone deacetylase","graph1":"Oncology","graph2":"Phase II","graph3":"HUYA Bioscience International","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HUYA Bioscience International \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"HUYA Bioscience International \/ Undisclosed"},{"orgOrder":0,"company":"Shenzhen Chipscreen Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Chidamide","moa":"||enzyme inhibitors: inhibitors of histone deacetylase","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shenzhen Chipscreen Biosciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shenzhen Chipscreen Biosciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Shenzhen Chipscreen Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Public Health Clinical Center","sponsor":"Ascletis Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Envafolimab","moa":"||Programmed cell death 1 ligand 1","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Shanghai Public Health Clinical Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Public Health Clinical Center \/ Ascletis Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Shanghai Public Health Clinical Center \/ Ascletis Pharma"},{"orgOrder":0,"company":"United BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Chidamide","moa":"||T-cell surface antigen CD4","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"United BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"United BioPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"United BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"United BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Chidamide","moa":"||T-cell surface antigen CD4","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"United BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"United BioPharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"United BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Shenzhen Chipscreen Biosciences","sponsor":"Peng Liu","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2018","type":"Inapplicable","leadProduct":"Chidamide","moa":"enzyme inhibitors: inhibitors of histone deacetylase","graph1":"Oncology","graph2":"Phase II","graph3":"Shenzhen Chipscreen Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shenzhen Chipscreen Biosciences \/ Peng Liu","highestDevelopmentStatusID":"8","companyTruncated":"Shenzhen Chipscreen Biosciences \/ Peng Liu"}]
Find Clinical Drug Pipeline Developments & Deals for Chidamide
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
